[go: up one dir, main page]

DE60109443D1 - Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält - Google Patents

Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Info

Publication number
DE60109443D1
DE60109443D1 DE60109443T DE60109443T DE60109443D1 DE 60109443 D1 DE60109443 D1 DE 60109443D1 DE 60109443 T DE60109443 T DE 60109443T DE 60109443 T DE60109443 T DE 60109443T DE 60109443 D1 DE60109443 D1 DE 60109443D1
Authority
DE
Germany
Prior art keywords
inosin
peptide
polycapic
cytosine
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60109443T
Other languages
English (en)
Other versions
DE60109443T2 (de
Inventor
Alena Egyed
Karen Lingnau
Frank Mattner
Michael Buschle
Walter Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Application granted granted Critical
Publication of DE60109443D1 publication Critical patent/DE60109443D1/de
Publication of DE60109443T2 publication Critical patent/DE60109443T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/18Type of nucleic acid acting by a non-sequence specific mechanism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60109443T 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält Expired - Lifetime DE60109443T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT10002000 2000-06-08
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
PCT/EP2001/006437 WO2001093903A1 (en) 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine

Publications (2)

Publication Number Publication Date
DE60109443D1 true DE60109443D1 (de) 2005-04-21
DE60109443T2 DE60109443T2 (de) 2006-04-13

Family

ID=3683921

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60109443T Expired - Lifetime DE60109443T2 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Country Status (7)

Country Link
US (2) US7148191B2 (de)
EP (1) EP1286695B1 (de)
AT (2) AT410173B (de)
AU (1) AU2001262345A1 (de)
DE (1) DE60109443T2 (de)
WO (1) WO2001093903A1 (de)
ZA (1) ZA200209479B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046224A2 (en) * 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
HU228264B1 (en) * 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
EP1350262B8 (de) * 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
CA2433561C (en) * 2001-01-03 2014-04-01 Willmar Poultry Company, Inc. Compositions including gram negative siderophore receptor proteins and methods of use
EP1347776A2 (de) * 2001-01-05 2003-10-01 Intercell Biomedizinische Forschungs- und Entwicklungs AG Gebrauch von polykationen als entzündungshemmende mittel
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
US20050250716A1 (en) * 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
CN1659436A (zh) * 2002-02-28 2005-08-24 英特塞尔股份公司 分离配体的方法
AU2003243161A1 (en) * 2002-04-24 2003-11-10 The Regents Of The University Of California Methods for stimulating tlr/irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses
ATE535231T1 (de) * 2002-07-03 2011-12-15 Oncovir Inc Verfahren zur herstellung von poly-iclc und seine verwendung
CA2484941A1 (en) * 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
CA2484339A1 (en) * 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP2314604A3 (de) 2002-10-15 2011-05-25 Intercell AG Bindungdsfaktoren von Gruppe B-Streptococcus, dafür kodierende Nukleinsäuren und Verwendungen davon
WO2004055041A2 (en) * 2002-12-13 2004-07-01 Case Western Reserve University Defensin-inducing peptides from fusobacterium
DK1601770T3 (da) 2003-03-04 2009-11-02 Intercell Ag Streptococcus pyogenes antigener
AU2004224747A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of Alum and a th1 immune response inducing adjuvant for enhancing immune responses
CA2517673C (en) * 2003-03-24 2013-08-13 Intercell Ag Improved vaccines for preventing viral infection
ATE449177T1 (de) 2003-03-31 2009-12-15 Intercell Ag Staphylococcus epidermidis antigene
CN102174534A (zh) 2003-04-15 2011-09-07 英特塞尔股份公司 肺炎链球菌抗原
EP2287177A3 (de) 2003-05-07 2011-08-31 Intercell AG Streptococcus agalactiae-Antigene I + II
EP2327720A1 (de) 2003-05-30 2011-06-01 Intercell AG Enterokokken-Antigene
US8329192B2 (en) 2003-09-19 2012-12-11 Epitopix Llc Campylobacter polypeptides and methods of use
EP1804822B1 (de) * 2004-10-29 2009-07-22 Intercell AG Hcv impfstoff für chronische hcv patienten
US8007811B2 (en) 2005-02-14 2011-08-30 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
ES2400531T3 (es) 2006-06-28 2013-04-10 Statens Serum Institut Expansión del repertorio de los linfocitos T para incluir epítopos subdominantes mediante vacunación con antígenos administrados en forma de fragmentos proteicos o cócteles peptídicos
EP2319862A1 (de) 2006-07-07 2011-05-11 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
EP2269624A3 (de) 2007-01-12 2012-08-08 Intercell AG Schützende Proteine von S. agalactiae, Kombinationen davon und Verwendungsverfahren dafür
CA2680060A1 (en) * 2007-03-07 2008-09-12 Nventa Biopharmaceuticals Corporation Double-stranded locked nucleic acid compositions
CN102015754A (zh) 2007-05-02 2011-04-13 英特塞尔股份公司 克雷伯菌(Klebsiella)抗原
EP2012122A1 (de) 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
CN101883782A (zh) 2007-06-18 2010-11-10 英特塞尔股份公司 衣原体抗原
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20110038888A1 (en) * 2008-01-10 2011-02-17 Peter Emtage Adjuvant compositions comprising poly-ic and a cationic polymer
JP2011514167A (ja) 2008-03-17 2011-05-06 インターセル アーゲー 肺炎連鎖球菌(S.pneumoniae)に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
EP3725328A3 (de) 2008-06-27 2020-12-23 Zoetis Services LLC Neue adjuvante zusammensetzungen
EP2424882A2 (de) 2009-02-05 2012-03-07 Intercell AG Gegen e.-faecalis schützende peptide, verfahren und anwendungen, die damit in zusammenhang stehen
EP2405938A2 (de) 2009-02-13 2012-01-18 Intercell AG Nicht typisierbare haemophilus influenza-antigene
CA2756313A1 (en) 2009-03-23 2010-09-30 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
EP2308896A1 (de) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
RU2558301C2 (ru) 2009-10-09 2015-07-27 Санофи Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие
EP2319871A1 (de) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
SI2753352T2 (sl) 2010-09-03 2022-10-28 Valneva Austria Gmbh Izoliran polipeptid proteinov toksina a in toksina b c. difficile in njegova uporaba
WO2012031760A1 (en) 2010-09-08 2012-03-15 Medigene Ag Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
CN105764525A (zh) 2013-09-19 2016-07-13 硕腾服务有限责任公司 油基佐剂
PL3244920T3 (pl) 2015-01-16 2023-09-25 Zoetis Services Llc Szczepionka przeciw pryszczycy
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
WO2019158636A1 (en) 2018-02-16 2019-08-22 2A Pharma Ab Parvovirus structural protein for the treatment of autoimmune diseases
EP3527223A1 (de) 2018-02-16 2019-08-21 2A Pharma AB Mutiertes parvovirus-strukturprotein
MY208001A (en) 2019-05-20 2025-04-03 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
WO2020240268A1 (en) 2019-05-31 2020-12-03 Universidad De Chile An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
WO2022074061A1 (en) 2020-10-07 2022-04-14 Valneva Sweden Ab Cholera vaccine formulation
AU2022255923A1 (en) 2021-04-09 2023-08-31 Valneva Se Human metapneumo virus vaccine
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6801650D0 (pt) 1968-08-20 1973-03-07 R Maes Processo para preparacao de complexos geradores de interferon
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
CA2261892A1 (en) 1996-07-24 1998-01-29 Michelle M. Hanna Base-protected nucleotide analogs with protected thiol groups
AU2001267349A1 (en) * 2000-04-14 2001-10-30 Cistem Biotechnologies Gmbh Pharmaceutical preparations comprising modified peptides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung

Also Published As

Publication number Publication date
US20030162738A1 (en) 2003-08-28
AT410173B (de) 2003-02-25
DE60109443T2 (de) 2006-04-13
US20070218073A1 (en) 2007-09-20
EP1286695B1 (de) 2005-03-16
AU2001262345A1 (en) 2001-12-17
ATE290880T1 (de) 2005-04-15
EP1286695A1 (de) 2003-03-05
ATA10002000A (de) 2002-07-15
ZA200209479B (en) 2003-11-21
WO2001093903A1 (en) 2001-12-13
US7148191B2 (en) 2006-12-12

Similar Documents

Publication Publication Date Title
DE60109443D1 (de) Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE500323T1 (de) Subtilisin-variante
TR199900267T2 (xx) GnRH-L�kotoksin kimeralar�.
ATE380822T1 (de) Funf-helix protein
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE69824013D1 (de) Impfstoff gegen hpv
AR038568A1 (es) Anticuerpos anti-a beta y su uso
BG101103A (bg) Теломераза при бозайници
BR0311693A (pt) Sal de formato de o-desmetil-venlafaxina
ATE79138T1 (de) Typenspezifische papillomavirus-dns-sequenzen und peptide.
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
ATE384119T1 (de) Isoprenoidproduktion
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
HUP9901112A2 (hu) Szintetikus HIV-gének
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
DE69515340D1 (de) Impfstoff gegen mycobakterielle infektionen
ATE321853T1 (de) Humanische pellino-polypeptide
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
EP1279677A4 (de) Gd3 mimetische peptide(05.11.01)
HUT77029A (hu) A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk
TW200505943A (en) Polypeptide
BR0316544A (pt) Compostos calcilìticos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition